Thomas Johnson is an Ophthalmology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 NW 17th Ave
Miami, FL 331016960
Telephone
305-326-6031Registry record last updated 4 May 2012.
Clinical trials
- ILUMIEN-V - AERO: All-comEr Registry of OCT (AERO)
Sponsor: IHF GmbH - Institut für Herzinfarktforschung
- Effect of Ultrasound Guided Laser Ablation Therapy on Symptomatic Benign Thyroid Nodules
Sponsor: Johnson Thomas
- Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
Sponsor: The National Retina Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20251 payment
- Tarsus Pharmaceuticals, Inc.Program year20242 payments
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
55.7%Aminoglycoside Antibacterial51.1%Neomycin-Polymyxin-Dexameth100%Part D≥89 patientsCorticosteroid4.6%Prednisolone Acetate100%Part D<11 patientsAnti-infectives
30.5%Macrolide30.5%Erythromycin100%Part D≥57 patientsCancer & immunology
8.9%Calcineurin inhibitor8.9%Cyclosporine56%Restasis44%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”